ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Persistent Methicilin-Resistant Staphylococcus aureus Bacteremia: Resetting the Clock for Optimal Management.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial.Microbiology spectrum · 2026Trial
- Genomic investigation and clinical correlates of theAntimicrobial agents and chemotherapy · 2024Trial
- Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial.Nature medicine · 2023Trial
- Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026Review
- Article
- Treatment of Methicillin-ResistantMedicines (Basel, Switzerland) · 2026Review
- Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of HumanAntibiotics (Basel, Switzerland) · 2026Article
- Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment.Nature reviews. Microbiology · 2026Review
- Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold.Nature communications · 2025Article
- Factors associated with persistent bacteraemia among patients with suspected infective endocarditis.Infection · 2025Article
- Enhanced Killing of Methicillin-Resistant Staphylococcus aureus With Ceftaroline or Vancomycin in Combination With Carbapenems.The Journal of infectious diseases · 2025Article
- A multi-hospital, clinician-initiated bacterial genomics programme to investigate treatment failure in severe Staphylococcus aureus infections.Nature communications · 2025Article
- Effective Management of a Skin and Soft Tissue Infection Caused by Community-Acquired MRSA Through Triple-Targeted Therapy Along with Aggressive Source Control: A Case Report.Infectious disease reports · 2025Article
- Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia.BMC infectious diseases · 2025Article
- Incidence, Clinical Characteristics and Outcomes of PersistentInfection and drug resistance · 2025Article
- Thirty-Day Mortality of Persistent Methicillin-ResistantYonsei medical journal · 2024Article
- Excess burden of antibiotic-resistant bloodstream infections: evidence from a multicentre retrospective cohort study in Chile, 2018-2022.Lancet regional health. Americas · 2024Article
- Article
- The Complex Intracellular Lifecycle ofInternational journal of molecular sciences · 2024Review
- A Retrospective Cohort Study Comparing Dual Therapy With Ceftaroline With Vancomycin or Daptomycin Monotherapy for High-Grade or Persistent MRSA Bacteremia.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
A positive follow-up blood culture for methicillin-resistant Staphylococcus aureus (MRSA) while on seemingly appropriate therapy is a common and ominous development. However, the definition and management of persistent MRSA bacteremia is unstandardized. In this Opinion Paper, we identify the presence of bacteremia for > 1 calendar day as a "worry point" that should trigger an intensive diagnostic evaluation to identify metastatic infection sites. Next, we define the duration of MRSA bacteremia that likely constitutes antibiotic failure and outline a potential management algorithm for such patients. Finally, we propose pragmatic clinical trial designs to test treatment strategies for persistent MRSA bacteremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.